A plan to expand the use of Acadia Pharmaceuticals’ only approved medicine to cover the treatment of patients with schizophrenia was dealt a setback on Monday with the failure of a late-stage clinical trial, the company said.
The Acadia drug, called Nuplazid, failed to improve the overall symptoms of schizophrenia compared with a placebo. The Phase 3 study enrolled nearly 400 schizophrenia patients with moderate to severe psychotic symptoms inadequately controlled by currently approved drugs.
Nuplazid, which is also known by its scientific name pimavanserin, is currently approved to treat psychosis related to Parkinson’s disease. The study, called ENHANCE, was Acadia’s first effort to expand the use of Nuplazid into a related indication.
About the Author Reprints
If I had schizophrenia, I would do a one time visit to a traditional Chinese medicine doctor. Usually in a local chinatown. Seems to be a lot more health in that country than here.
Does this imply that the neuropathology of Parkinson’s psychosis is different than the neuropathology of schizophrenia?